New hope for Hard-to-Treat uterine cancer: targeted drug trial underway

NCT ID NCT06369155

Recruiting now Disease control Sponsor: Joyce Liu, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called azenosertib in 25 women with a rare and aggressive type of uterine cancer that has come back or not gone away. The goal is to see how the drug affects cancer cells and whether it can shrink tumors or slow the disease. Participants take the drug and have regular scans and biopsies to track results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma uterine cancer uterine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UTERINE CANCER UTERINE CARCINOMA UTERINE SEROUS CARCINOMA

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.